Prelude Therapeutics Inc (PRLD) Form 8-K — Aug 11, 2026
Prelude Therapeutics reported a second quarter 2026 net loss of $13.9 million, or $0.14 per share, versus a $31.2 million, or $0.41 per share loss a year earlier, as R&D expense fell to $16.1 million from $25.8 million following the 2025 pause of its SMARCA2 clinical trials and a workforce reduction. The quarter also included $5.7 million of revenue versus none in the prior-year period, tied to its partnership activity. The company held $155.2 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026, and expects that balance to fund operations into the second quarter of 2028.
Key figures
- Revenue
- 5704000
- Total Assets
- 189363000
- Cash Position
- 155200000
- Shares Outstanding
- 65,028,996 voting common shares and 14,728,135 non-voting common shares outstanding as of June 30, 2026
- Cash Runway
- into the second quarter of 2028
- Restricted Cash
- 3405000
- Ga Expense Q2 2025
- 6410000
- Ga Expense Q2 2026
- 5027000
- Total Liabilities
- 55630000
- Rnd Expense Q2 2025
- 25784000
- Rnd Expense Q2 2026
- 16131000
- Revenue Prior Year Q2
- 0
- Stockholders Equity
- 133733000
- Marketable Securities
- 125428000
- Cash And Cash Equivalents
- 26329000
- Deferred Revenue Current
- 25248000
- Weighted Average Shares Basic And Diluted
- 98388593
Price after filing
Close on the filing date to close N calendar days later (from $4.90). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.